Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

Trial Details

NCT ID
NCT05579366
Phase
PHASE1 / PHASE2
Sponsor
Genmab
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • Rina-S
  • Carboplatin
  • Bevacizumab
  • Pembrolizumab
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Los Angeles, California, United States|34.05223,-118.24368
  • Santa Barbara, California, United States|34.42083,-119.69819
  • Fort Myers, Florida, United States|26.62168,-81.84059
  • Augusta, Georgia, United States|33.47097,-81.97484

Key Eligibility Criteria

  • Part A and B:
  • Histologically or cytologically confirmed metastatic or unresectable solid malignancy including ovarian cancer (must have epithelial ovarian cancer…
  • Previously received therapies known to confer clinical benefit.
  • Measurable disease per RECIST v1.1 for all tumor types other than pleural mesothelioma which will use mRECIST v1.1 at baseline.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →